Navigation Links
Pharmacyclics Reports Third Quarter 2013 Results
Date:11/7/2013

Q under the symbol PCYC. To learn more about how Pharmacyclics advances science to improve human healthcare visit us at http://www.pharmacyclics.com.

Use of Non-GAAP Financial MeasuresThis press release contains non-GAAP financial measures, including operating expenses and other expenses adjusted to exclude certain non-cash expenses. These measures are not in accordance with, or an alternative to, generally accepted accounting principles, or GAAP, and may be different from non-GAAP financial measures used by other companies. The items included in GAAP presentations but excluded for purposes of determining non-GAAP financial measures for the periods presented in this press release are employee related non-cash expenses. The Company believes the presentation of non-GAAP financial measures provides useful information to management and investors regarding various financial and business trends relating to our financial condition and results of operations. When GAAP financial measures are viewed in conjunction with non-GAAP financial measures, investors are provided with a more meaningful understanding of our ongoing operating performance. In addition, these non-GAAP financial measures are among those indicators the Company uses as a basis for evaluating operational performance, allocating resources and planning and forecasting future periods. Non-GAAP financial measures are not intended to be considered in isolation or as a substitute for GAAP financial measures. To the extent this release contains historical or future non-GAAP financial measures, the Company has also provided corresponding GAAP financial measures for comparative purposes. Reconciliation between certain GAAP and non-GAAP measures is provided below.

NOTE: This announcement may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related medicine technology :

1. Pharmacyclics Announces Date of Conference call to discuss Financial Results for Third Quarter Ended September 30, 2013
2. Pharmacyclics Reports Second Quarter 2013 Results
3. Pharmacyclics Announces Date of Financial Results for Second Quarter Ended June 30, 2013 and Conference Call
4. Pharmacyclics Reports First Quarter 2013 Results
5. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
6. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
7. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
8. Pharmacyclics, Inc. Prices Public Offering of Common Stock
9. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
10. Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
11. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... , July 31, 2015 Egalet Corporation ... specialty pharmaceutical company focused on developing, manufacturing and ... of its previously announced underwritten public offering of ... public offering price of $11.25 per share. The ... 1,000,000 shares issued upon the exercise in full ...
(Date:7/31/2015)... SAN DIEGO , July 31, 2015  Eisai ... Ltd. (Headquarters: Tokyo , President and ... Inc. (Headquarters: San Diego, California , ... HALO") have signed a clinical collaboration agreement to evaluate ... in combination with Halozyme,s investigational drug PEGPH20 (PEGylated recombinant ...
(Date:7/31/2015)... CHICAGO , July 31, 2015 ... Composition Analyzers Market by Product (Bioimpedance Analyzers (BIA), Dual-Energy ... and Hydrostatic Weighing) - Global Analysis & Forecast to ... Market was pegged at $911.1 Million 2014 and is ... at a CAGR of 9.4% from 2014 to 2019. ...
Breaking Medicine Technology:Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6Body Composition Analyzers Market Worth $1,425.7 Million by 2019 2Body Composition Analyzers Market Worth $1,425.7 Million by 2019 3Body Composition Analyzers Market Worth $1,425.7 Million by 2019 4
(Date:7/31/2015)... ... 2015 , ... Transfinder, a software company based in Schenectady, N.Y., achieved record ... year-over-year for the first six months ended June 30, 2015 compared with the same ... last year’s record-revenue mark of $10.4 million. , “We know what our customers need ...
(Date:7/31/2015)... ... July 31, 2015 , ... The Mount Sinai Health System will work ... the potential of related, experimental treatments. The collaboration moves into the next phase with ... Care one of five state licenses to produce and dispense medical marijuana. , ...
(Date:7/31/2015)... ... July 31, 2015 , ... Successful Import/Export ... http://www.fdanews.com/importexportprogram , Having FDA-regulated products held at ports costs time, money ... risking containment — or even destruction — of products, an FDA insider shows ...
(Date:7/31/2015)... NY (PRWEB) , ... July 31, 2015 , ... Patients ... disease, according to a study published today in Nature Communications and led by researchers ... in mice, suggests that variations in the gene RTN1 led to greater production of ...
(Date:7/31/2015)... ... ... Down is a reputable source of authentic USA vs. Australia tickets at Ford ... National Team in conjunction with their Victory Tour to celebrate winning the 2015 Women's World ... team was awarded the Golden Ball as the best player of the 2015 Women's World ...
Breaking Medicine News(10 mins):Health News:Transfinder Closes First Half of 2015 with Record Revenue 2Health News:Mount Sinai to Collaborate with Columbia Care on Medical Marijuana Research 2Health News:Mount Sinai to Collaborate with Columbia Care on Medical Marijuana Research 3Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 2Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 3Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 4Health News:Mount Sinai Researchers Find Key Gene Drives Kidney Disease Severity 2Health News:Mount Sinai Researchers Find Key Gene Drives Kidney Disease Severity 3Health News:Cheap USA vs. Australia Tickets at Ford Field in Detroit, MI: Ticket Down Slashes Ticket Prices for Australia vs. USWNT International Friendly Match at Ford Field 2
... the most commonly reported vector-borne disease in the United States, ... has been three decades since the agent of the disease, ... vector it were identified. However, the number of Lyme disease ... in the forthcoming issuue of the Journal of Medical ...
... Reporter , WEDNESDAY, Jan. 4 (HealthDay News) -- Some people ... chemotherapy, and a mutation in the so-called TFAP2E gene may ... Knowing which patients carry the mutation might help ... researchers said. "In our study, we identified a gene ...
... By Amanda Gardner HealthDay Reporter , WEDNESDAY, Jan. ... and deaths in the United States in recent years are charted ... for cancer went down by 1.8 percent a year in men ... (ACS) reported Wednesday. And from 1990 through 2008, death rates ...
... 2012-PORTLAND, Ore. When patients with diabetes experience interruptions in ... the screening tests and vaccines they need to protect their ... when patients receive free or reduced-cost medical care at federally ... part by the National Institutes of Health and findings published ...
... , WEDNESDAY, Jan. 4 (HealthDay News) -- Remember those ... but you took the plunge and whizzed downward. Next, ... and hanging by your knees at the pinnacle. ... sliding boards, safer plastic climbers and fence-protected platforms are ...
... ANGELES Marianne Gausche-Hill, M.D., and Kate Remick, M.D. ... Institute at Harbor-UCLA Medical Center (LA BioMed) are ... Jan. 6, 2012 that will help assess the pediatric ... the first statewide survey of its kind, this project ...
Cached Medicine News:Health News:How can Lyme disease be prevented and controlled? 2Health News:Gene Mutation Linked to Chemo-Resistant Colon Cancer 2Health News:Cancer Incidence, Death Rates Continue to Drop: Report 2Health News:Cancer Incidence, Death Rates Continue to Drop: Report 3Health News:Kaiser Permanente study finds continuous health coverage essential for patients managing diabetes 2Health News:'Safety-First' Playgrounds Linked to Bored, Inactive Kids: Study 2Health News:'Safety-First' Playgrounds Linked to Bored, Inactive Kids: Study 3Health News:LA BioMed investigators lead first survey to determine hospital EDs' pediatric readiness 2
The RapidBARBITURATE test is an immunochromatography based one step in vitro test. It is designed for qualitative determination of barbiturates and in human urine specimens above a cut-off level of 3...
... With membrane parasite ... and cytoplasm as antigen. ... different antigens than the ... possible to use two ...
Elisa test for qualitative detection of Total antibodies to Trypanosoma Cruzi in human serum or plasma....
Silicone ICD lead...
Medicine Products: